Nicole Wyatt

Nicole Wyatt

Auto-generated profile, based on publicly available information

Nicole Wyatt

Division of Nephrology and Hypertension, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2020 in Cureus
Verified
Journal Article
Open access
PDF file
BHBrittany Hill
Brittany Hill
NWNicole Wyatt
Nicole Wyatt
DEDavid Ennis
David Ennis
Cerebral toxoplasmosis is a life-threatening infection most commonly found in immunocompromised hosts such as acquired immunodeficiency syndrome (AIDS) or transplant patients. However, it is not known to affect patients with chronic inflammatory disorders on immunosuppressive therapy. We describe the case of a 70-year-old female with rheumatoid arthritis (RA) on chronic therapy with methotrexate and infliximab, who presented to the hospital after two weeks of right-sided weakness. Imaging revealed bilateral ring-enhancing lesions in the basal ganglia (left greater than right). A diagnosis of cerebral toxoplasmosis was made on brain biopsy. Apart from the immunosuppressive therapy and owning a cat, she had no other risk factors for developing the infection. The patient’s immunosuppressive medications were discontinued, and she was started on high-dose trimethoprim-sulfamethoxazole (TMP-SMX). Upon literature review using PubMed, we found seven other published reports on similar cases of toxoplasmosis in RA patients on immunosuppressive therapy; however, there was a lack of recommendations for diagnosis, treatment, and prophylaxis in this patient population. With the growing use of immunosuppressive therapies in chronic inflammatory disorders, further data is needed regarding the management of toxoplasmosis in these patients. This case report is an investigation of the relationship between immunosuppressive medications in RA patients and cerebral toxoplasmosis and an exploration of the available recommendations for its management.

7 May 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
NWNicole E. Wyatt
Nicole E. Wyatt
VDVimal K. Derebail
Vimal K. Derebail
RFRonald J. Falk
Ronald J. Falk
KJKoyal Jain
Koyal Jain
ANCA-associated vasculitis (AAV) is a rare and potentially fatal autoimmune disorder characterized by pauci-immune necrotizing vasculitis affecting small- to medium-sized blood vessels. The pathogenic role of ANCAs in AAV is supported by both clinical and experimental evidence, and when used in the proper clinical setting, ANCA testing is highly specific for AAV. Testing with both indirect immunofluorescence assay and enzyme immunoassay may increase sensitivity for AAV; however, testing with a high-quality enzyme immunoassay may be used alone. Nonvasculitic conditions and drugs can cause ANCA positivity without manifestations of AAV. We review ANCA testing itself, performance characteristics and specific conditions for the laboratory test, and various conditions when ANCA testing is useful in diagnosis, disease monitoring, and selecting treatment.

8 July 2024 in Kidney360
Verified
Journal Article
Open access
OSOsama El Shamy
Osama El Shamy
NWNicole Wyatt
Nicole Wyatt
SPSagar Patel
Sagar Patel
NANaief Abudaff
Naief Abudaff
RGRobert Greevy
Robert Greevy
TGThomas Alan Golper
Thomas Alan Golper
Key Points: There is a consistent increase in ultrafiltration volumes achieved per cycle over the course of an automated peritoneal dialysis treatment session. A better understanding of intercycle ultrafiltration trends may inform prescription interventions that can improve patient retention. Surface area recruitment, mesenteric elasticity, and cumulative glucose concentration in the interstitium are possible explanations for our findings. Background: With the growing use of automated peritoneal dialysis (APD), it is important to improve our knowledge of the clinical patterns and physiology of APD treatment sessions. The ultrafiltration (UF) achieved during each cycle of an APD treatment is assumed to be relatively linear if the delivered prescription is the same. We set out to determine whether that is indeed the case. Methods: This is a single-center, cross-sectional study of patients on prevalent peritoneal dialysis (PD). All adult patients on APD (older than 18 years) who had been on PD for ≥3 months and ≥3 months on APD were included. Patients on continuous ambulatory PD or those with peritonitis within 3 months of the consent date were excluded. Individual treatment data from seven consecutive APD treatment sessions with consistent dialysate composition for each cycler exchange were collected for each patient. Results: Thirty-nine patients met the inclusion criteria and were enrolled. The probability of yielding a positive UF was 48.9% for cycle 1, rising to 90.5% by cycle 6. Adjusting for average dextrose concentration, dwell time, fill volume, solute transfer rate, and number of cycles, we observed that cycles 2–6 achieved progressively higher UF volumes than cycle 1 (P < 0.001). The first and last cycles demonstrated significantly different cycle UF volumes compared with a middle cycle (−230 and 277 ml, respectively, P < 0.001). Conclusions: We observed a consistent increase in UF volumes achieved per cycle over the course of an APD treatment session with numerous clinical and physiologic implications. This provides the foundation for future studies investigating peritoneal intercycle variations and membrane physiology.

11 November 2025 in Journal of Intensive Care Medicine
Verified
Journal Article
Open access
TRTrey Richardson
Trey Richardson
NWNicole Wyatt
Nicole Wyatt
JLJasiu Latocha
Jasiu Latocha
EKEthan Kefauver
Ethan Kefauver
ESEdward D. Siew
Edward D. Siew
Intravenous crystalloid solutions are among the most common medical interventions applied and have supplanted colloid-based solutions as the standard of care for volume resuscitation in most settings. Despite their widespread use, debate has existed over the optimal composition of these solutions and their differential effects on patient outcomes. In this review, we will describe the pre-clinical studies that identified physiological differences when ‘balanced crystalloids’ and ‘normal saline’ are administered, the experimental studies that confirmed these differences in humans, the observational studies that indicated the level of concern, and the subsequent clinical trials that provide evidence to guide therapy in current practice.